EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Preferences for oral and injectable PrEP among qualitative sub-study participants in HPTN 084

Elizabeth E Tolley iD, Agatha Bula, Miria Chitukuta, Nomhle Ndimande-Khoza, Juliane Etima, Emily Namey, Doreen Kemigisha, Lerato Makhale, Mercy Tsidya, Marie Shoen iD, Mina C Hosseinipour iD, Sinead Delany-Moretlwe und 1 weitere

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0309811 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Elizabeth E Tolley und 12 weiteren Autor:innen. Beteiligte Einrichtung: FHI 360, Durham, North Carolina, United States of America. Hauptthemen laut MEDLINE: HIV Infections, Pre-Exposure Prophylaxis, Anti-HIV Agents. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases, NIH Office of the Director.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

HPTN 084 compared the safety and efficacy of long-acting injectable cabotegravir (CAB) to daily oral TDF/FTC for prevention of HIV-1 in uninfected African women. Like a similar trial in MSM/TGW (HPTN 083), the trial was stopped early for efficacy, expediting the need to consider introduction strategies for different populations. We examine survey and qualitative data from a four-country sub-study to examine oral and injectable PrEP acceptability and considerations for CAB access among African women.

Methods

Participants completed baseline and follow-up surveys on HIV risk perception, sexual behavior. product acceptability and adherence during the blinded trial. Additionally, up to two in-depth interviews each with 73 sub-study participants explored product use and trial-related experiences, during the blinded and unblinded study periods. Using survey data, we classified participants as: engaged in female sex work (FSW), having multiple non-transactional partners, or monogamous. A study statistician identified participants’ assigned study arm. We followed a thematic analysis process to read transcripts, develop a codebook and apply codes in NVivo to transcripts with intermittent intercoder reliability checks; using Excel matrices to explore differences across risk categories and study arms.

Findings

Participants overwhelmingly preferred injections to pills, appreciating the ease, convenience, and privacy of a long-acting formulation. Many participants described challenges with contraceptive and/or study pill adherence, impeded by late night work, unexpected travel, or heavy drinking. Women in the TDF/FTC arm were more likely to describe side effects, compared to those in the CAB arm. Pain also varied widely by study arm. When considering post-trial access to CAB, limited PrEP knowledge, cost and concerns around stigma and poor service quality were potential access barriers.

Conclusion

Women’s desire for privacy and ease of use outweighed injectable concerns, resulting in a strong preference for CAB. Cost and accessibility will need to be addressed by implementation programs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsPre-Exposure ProphylaxisAnti-HIV AgentsHumansFemaleAdultAdministration, OralInjectionsYoung AdultSexual BehaviorPatient PreferencePyridonesDiketopiperazines

Substanzen

Anti-HIV AgentscabotegravirPyridonesDiketopiperazines

Autor:innen und Institutionen

  • FHI 360, Durham, North Carolina, United States of America.
  • UNC-Project Malawi, Malawi Clinical Research Site, Lilongwe, Malawi.
  • University of Zimbabwe Clinical Trials Research Centre (UZCTRC) - Spilhaus Clinical Research Site, Harare, Zimbabwe.
  • Wits RHI, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
  • Makarere-Johns Hopkin University Clinical Research Site, Kampala, Uganda.
  • University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, United States of America.

ORCID-Profile: Elizabeth E Tolley, Marie Shoen, Mina C Hosseinipour

Förderung

  • NIAID NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • NIH Office of the Director
  • National Institutes of Health
  • National Institute on Drug Abuse
  • National Institute of Mental Health
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development
  • Bill & Melinda Gates Foundation

Zitieren

APA

Tolley, E. E., Bula, A., Chitukuta, M., Ndimande-Khoza, N., Etima, J., Namey, E., Kemigisha, D., Makhale, L., Tsidya, M., Shoen, M., Hosseinipour, M. C., Delany-Moretlwe, S., & HPTN 084 study team (2024). Preferences for oral and injectable PrEP among qualitative sub-study participants in HPTN 084. PLOS ONE. https://doi.org/10.1371/journal.pone.0309811

Vancouver

Tolley EE, Bula A, Chitukuta M, Ndimande-Khoza N, Etima J, Namey E, et al. Preferences for oral and injectable PrEP among qualitative sub-study participants in HPTN 084. PLOS ONE. 2024. doi:10.1371/journal.pone.0309811

BibTeX
@article{Tolley2024,
  author = {Tolley, Elizabeth E and Bula, Agatha and Chitukuta, Miria and Ndimande-Khoza, Nomhle and Etima, Juliane and Namey, Emily and Kemigisha, Doreen and Makhale, Lerato and Tsidya, Mercy and Shoen, Marie and Hosseinipour, Mina C and Delany-Moretlwe, Sinead and HPTN 084 study team, HPTN 084 study team},
  title = {Preferences for oral and injectable PrEP among qualitative sub-study participants in HPTN 084},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0309811}
}
Kostenlos starten →